Fluicell publishes 2023 Half-year report

Today, August 2023, Fluicell publishes the financial report for the period January 1 to June 30, 2023. The…

Read more
18 Aug 2023

Microenvironment modeling with high precision bioprinitng

The cell microenvironment plays a key role in many biological processes. Replicating the cell microenvironment and the complex…

Read more
05 Jul 2023

New study reveals potential treatment for premenstrual dysphoric disorder

Premenstrual dysphoric disorder (PMDD) is a mood disorder affecting up to 8% of all menstruating women that greatly…

Read more
28 Jun 2023

Fluicell CEO Newsletter 02, 2023

Changing research at the core has been a driving force for us at Fluicell from the start. Through…

Read more
14 Jun 2023

Fluicell Capital Markets Day

Updtae 2023-05-23 All the talks from the Capital Markets Day are now available here: https://fluicell.com/capital-markets-day-2023/. You can also…

Read more
22 May 2023

“Fluicell is advancing in the right direction” interview with CEO Victoire Viannay

Our plan is to continue to advance in all our three business areas: research solutions, human in vitro…

Read more
19 May 2023

Closing the loop on type 1 diabetes – therapeutic development whitepaper

Fluicell’s type 1 diabetes development program is aimed at creating patient-tailored artificial pancreatic islets capable of enabling glycemic…

Read more
16 May 2023

Fluicell publishes 2023 Q1 interim report

Today, May 12 2023, Fluicell publishes the Q1 interim report for the period January to March, 2023. The…

Read more
12 May 2023

90 students experience bioprinting at Fluicell

We at Fluicell are passionate about research and science and always want to take the opportunity to inspire…

Read more
08 May 2023